DHSC

Intravacc Awarded US$ 633K CARB-X Funding to Develop a Vaccine that Prevents Gonorrhea Infections

Retrieved on: 
Tuesday, January 16, 2024
Development, Agreement, Patient, Infection, Ceftriaxone, Infertility, Social work, Science, Gonorrhea, STI, Administration, Pelvic inflammatory disease, Vaccination, Bill, Risk, Education, Bacteria, Neisseria gonorrhoeae, Disease, BMBF, Doctor of Philosophy, HIV, Human services, Vaccine, Chronic pain, DHSC, OMV

The Neisseria gonorrhoeae bacterium causes gonorrhea, the second most reported bacterial STI.

Key Points: 
  • The Neisseria gonorrhoeae bacterium causes gonorrhea, the second most reported bacterial STI.
  • Patients with gonorrhea can face serious health effects, including pelvic inflammatory disease, chronic pain, infertility, and an increased risk of contracting HIV.
  • Through the tailored gonococcal antigens on the surface of the meningococcal OMV, Intravacc anticipates a significant enhancement in the vaccine candidate’s efficacy against gonorrhea.
  • “This CARB-X project allows us to combine our science and OMV expertise for the development of a vaccine against gonorrhea infections.

LimmaTech Biologics Expands Vaccine Pipeline by Licensing AbVacc’s Innovative Vaccine Candidate Against Staphylococcus aureus

Retrieved on: 
Tuesday, December 19, 2023
Research, Infectious Diseases, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Rabbit, Infection, Multimedia, NIAID, Toxoid, Administration, Staphylococcus aureus, Mouse, Doctor of Philosophy, Recurrence, DHSC, Human services, REPAIR, Education, Bangladesh Technical Education Board, S. aureus, Staphylococcus, Patient, Development, BMBF, Social work, Skin, CARB-X, Vaccine

LimmaTech Biologics and AbVacc announced today a license agreement that grants LimmaTech the exclusive rights to further develop AbVacc’s multivalent toxoid vaccine candidate, LBT-SA7 (formerly IBT-V02), designed to prevent infections caused by the bacterial pathogen, Staphylococcus aureus (S. aureus).

Key Points: 
  • LimmaTech Biologics and AbVacc announced today a license agreement that grants LimmaTech the exclusive rights to further develop AbVacc’s multivalent toxoid vaccine candidate, LBT-SA7 (formerly IBT-V02), designed to prevent infections caused by the bacterial pathogen, Staphylococcus aureus (S. aureus).
  • LimmaTech also receives an exclusive option, executable post Phase 1 read-out, to acquire full rights to the program.
  • The vaccine candidate contains weakened forms of toxins, referred to as toxoids, that would normally be secreted by the pathogen to cause an infection.
  • Preclinical studies in mice and rabbits demonstrated strong neutralizing activity against several clinically relevant forms of S. aureus infection.

Emergex Signs Contract of £1.79M with the UK Department of Health and Social Care’s UK Vaccine Network (“UKVN”) to Advance Its Novel Synthetic T Cell-Priming Set-Point Candidate Against Chikungunya Virus

Retrieved on: 
Friday, November 17, 2023
UK Research and Innovation, Orthornavirae, Low, Good manufacturing practice, CHIKV, MHRA, Disease, DHSC, Government, Epitope, Epidemic, Research, Swiss Medical Students' Association, UKRI, Arthritis, Vaccine, AMR, CD8, Infection, CGMP, Pacific Ocean, News, RNA, Social work, Chikungunya, Dengue fever

In the last decade, CHIKV has become a reemerging mosquito-transmitted virus that has spread into Europe, Asia, the Pacific Region, and the Americas, with epidemics causing severe economic impact.

Key Points: 
  • In the last decade, CHIKV has become a reemerging mosquito-transmitted virus that has spread into Europe, Asia, the Pacific Region, and the Americas, with epidemics causing severe economic impact.
  • The programme is intended to position Emergex for entry to the clinic by its completion, ready to begin a Phase-1 clinical trial.
  • Subsequently, Emergex achieved all milestones priming the CHIKV candidate for progression to the next stage of its preclinical development.
  • A Phase-2 trial for CoronaTcP and a Phase-1 trial for a Universal Influenza vaccine candidate are planned in H1 2024.

Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea

Retrieved on: 
Wednesday, November 1, 2023
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Grand duchy, Food, Face, VWS, Disease, Gonorrhea, MHLW, Partnership, The Lancet, National Rural Development Partnership, Infection, Nursing care plan, Reproduction, SAMRC, Azithromycin, Hope, Physician, Prevalence, HIV, Ceftriaxone, BMBF, Neisseria gonorrhoeae, University, Therapy, Patient, Food and Drug Administration, Infertility, DFID, Heart, BMG, NIAID, MD, DHSC, AMR, BZ, Clinical trial, World Health Organization, Zoliflodacin, Woman, Multidrug-resistant bacteria, FOPH, South African Medical Research Council, Death, Ministry, Pharmaceutical industry, Vaccine, Medicine

These positive preliminary findings offer hope for patients with this condition, particularly in the face of rising antibiotic resistance to current regimens.

Key Points: 
  • These positive preliminary findings offer hope for patients with this condition, particularly in the face of rising antibiotic resistance to current regimens.
  • It also paves the way for a new research and development model in the global fight against antimicrobial resistance (AMR).
  • Now, the positive results of this landmark Phase 3 trial confirm that zoliflodacin has the potential to tackle the most difficult-to-treat gonorrhea infections.
  • This builds on the critical Phase 2 clinical trial sponsored by the U.S. National Institute of Allergy and Infectious Diseases (NIAID).

Protecting privacy during a pandemic: our work on the UK’s Covid apps

Retrieved on: 
Tuesday, April 25, 2023
Technology, Department, Social work, Health Protection Scotland, NHS COVID-19, ICO, API, DHSC, Privacy, Government, Department of Health and Social Care, NI, Health, Mobile phone

He led our operational response to the pandemic and leads our stakeholder relationships with the health and care sector.

Key Points: 
  • He led our operational response to the pandemic and leads our stakeholder relationships with the health and care sector.
  • In practice, the majority of our work to protect people’s privacy rights has a far lower profile.
  • Our work with the Department of Health and Social Care and Welsh Government around the NHS Covid app is a prime example.
  • We’re pleased that our work, started in March 2020, has helped to protect millions of people across the UK.

Emergex Generates Chikungunya Ligandome, a Milestone in the Development of its T cell Adaptive Vaccine

Retrieved on: 
Monday, November 28, 2022
Degenerative disease, MHC, Infection, UK Research and Innovation, Epitope, Public health, Innovation, Peptide, Laboratory, Allele, HLA, RNA, Cell, Developing country, IUK, Alphavirus, Department of Health and Social Care, Global health, Research, Medicine, Disease, UKRI, Government of the United Kingdom, Social work, CD8, Immortalised cell line, Human, DHSC, Organic acid, HLA-C, Vaccine, Pharmaceutical industry, Chikungunya, CHIKV

Abingdon, Oxon, UK, 28 November 2022 Emergex Vaccines Holding Limited (Emergex), a clinical-stage biotechnology company addressing major global infectious diseases through the development of fully synthetic CD8+ T cell Adaptive Vaccines, announces today that it has generated a Chikungunya (CHIKV) ligandome, the first major milestone in the development of Emergexs CD8+ T cell CHIKV Adaptive Vaccine candidate.

Key Points: 
  • Abingdon, Oxon, UK, 28 November 2022 Emergex Vaccines Holding Limited (Emergex), a clinical-stage biotechnology company addressing major global infectious diseases through the development of fully synthetic CD8+ T cell Adaptive Vaccines, announces today that it has generated a Chikungunya (CHIKV) ligandome, the first major milestone in the development of Emergexs CD8+ T cell CHIKV Adaptive Vaccine candidate.
  • The library of CHIKV ligandome peptides identified by Emergex will now enter the next phase of development.
  • Laurens Rademacher, Chief Technology Officer at Emergex commented: The ligandome identified allows the addition of a Chikungunya vaccine candidate to Emergexs pipeline.
  • The ligandome library which contains viral and self MHC class I peptides has been established successfully by using the Emergex proprietary vaccine development platform, which provides a rational basis for CD8+ T cell vaccine development.

DXC Technology Rolls Out Global Initiative to Support Neurodiversity in the Workplace

Retrieved on: 
Wednesday, October 12, 2022
Dyslexia, Technology, DHSC, EMEA, Cornell University School of Industrial and Labor Relations, Employment, Motivation, Disability studies, Department of Health and Social Care, NYSE, ADHD, UX, APAC, DXC Technology, Program, Autism, Workforce, Partnership, Cornell University, Department, Information technology, Social work, Information management, Workplace, United Kingdom, Environment, Foundation, DXC, Disability, Consultant, Management, Risk management, Creative industries

LONDON, Oct. 12, 2022 /PRNewswire/ -- DXC Technology (NYSE: DXC) a leading Fortune 500 global technology services provider, is expanding the DXC Dandelion Program which helps neurodivergent individuals with autism, ADHD, dyslexia and other neurological conditions to build careers in the IT industry.

Key Points: 
  • Following the success of the program in Australia and New Zealand, DXC is now launching the initiative across European and Asia Pacific countries.
  • The DXC Dandelion Program was launched in 2014 in Australia with a focus on creating employment pathways and careers for neurodivergent individuals within the IT industry.
  • With no prior professional experience required to participate, DXC has made the program available to individuals of all abilities with the motivation to work in technology.
  • In addition to offering employment, DXC provides participants with technical and vocational training plus professional support by specialised consultants.

DXC Technology Rolls Out Global Initiative to Support Neurodiversity in the Workplace

Retrieved on: 
Wednesday, October 12, 2022
Dyslexia, Technology, DHSC, EMEA, Cornell University School of Industrial and Labor Relations, Employment, Motivation, Disability studies, Department of Health and Social Care, NYSE, ADHD, UX, APAC, DXC Technology, Program, Consultant, Autism, Workforce, Multimedia, Partnership, Cornell University, Department, Information technology, Social work, Information management, Workplace, United Kingdom, Environment, Foundation, DXC, Disability, View, Management, Risk management, Creative industries

Following the success of the program in Australia and New Zealand, DXC is now launching the initiative across European and Asia Pacific countries.

Key Points: 
  • Following the success of the program in Australia and New Zealand, DXC is now launching the initiative across European and Asia Pacific countries.
  • The DXC Dandelion Program was launched in 2014 in Australia with a focus on creating employment pathways and careers for neurodivergent individuals within the IT industry.
  • With no prior professional experience required to participate, DXC has made the program available to individuals of all abilities with the motivation to work in technology.
  • In addition to offering employment, DXC provides participants with technical and vocational training plus professional support by specialised consultants.

Emergex Vaccines signs Heads of Terms for a Collaboration with Molecular Biology Institute of Paraná (IBMP) in Brazil

Retrieved on: 
Friday, July 1, 2022
Department, IBMP, Official development assistance, Research, UKM Medical Molecular Biology Institute, Molecular biology, COVID-19, Ministry, Ministry of Health (Bahrain), DHSC, Secretary of State for International Development, Innovate UK, Social, Vaccine, Innovation, SBRI, Dengue fever, Pharmaceutical industry, Health

In addition, clinical stage manufacturing of the vaccines will be conducted by Emergex with a transition to commercial scale manufacturing being conducted in the region by IBMP.

Key Points: 
  • In addition, clinical stage manufacturing of the vaccines will be conducted by Emergex with a transition to commercial scale manufacturing being conducted in the region by IBMP.
  • A Joint Steering Committee with representatives from both Emergex and IBMP will oversee the collaboration and commercialisation of the vaccines in Brazil.
  • The collaboration also involves Emergex and IBMP conducting pre-clinical testing and clinical development of Chikungunya vaccine candidate.
  • Partnering with IBMP makes strategic sense for Emergex as it has the local contacts and expertise to successfully develop and commercialize our vaccines in Brazil.

Cantourage kick-starts business in growing UK medical cannabis market with award of pharmaceutical licences and CQC registration to prescribe to patients

Retrieved on: 
Wednesday, April 13, 2022
EMA, Department of Health and Social Care, CEO, Care Quality Commission, Prescription, Social work, Plant, Narcotic, Medication, Compliance, Medicines and Healthcare products Regulatory Agency, GMP, Abuse, Department, European Medicines Agency, Patient, DHSC, Terpene, Home, Growth, Pharmacy, Health care quality, WDA, MHRA, Cannabidiol, Health care, CQC, Home Office, Drug, Medicine, Pharmaceutical industry, EU

LONDON and BERLIN, April 13, 2022 /PRNewswire/ -- European medical cannabis company Cantourage has received two British government licences that authorise the company to import medical cannabis into the UK. The company has also received the required regulatory registration to prescribe medical cannabis products to clients via a new facility, Cantourage Clinic.

Key Points: 
  • The company has also received the required regulatory registration to prescribe medical cannabis products to clientsvia a new facility, Cantourage Clinic.
  • In addition, Cantourage UK received regulatory registration for " Cantourage Clinic ", a private tele-healthcare clinic specialised in medical cannabis.
  • These three licences position Cantourage in the UK medicinal cannabis market, which is forecast to reach approximately US$1.3 billion with almost 400,000 patients by 2024[1].
  • Cantourage UK imports medical cannabis products from Germany into the UK and Channel Islands, supplying a broad range of products to patients throughout the country.